# XBIO earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XBIO) · [Earnings tab](https://www.lopjlb.com/stock/XBIO?tab=earnings)

Updated: 2026-08-07T06:11:15

Quarters analyzed: 2

## Cross-quarter narrative

Across the two calls, Xenetic Biosciences showed incremental progress with a slightly improved cash position ($4M to $4.3M) and a more positive management tone (0.00 to 0.7). The $3M Shire milestone was referenced in both periods, suggesting receipt. The NASDAQ listing mentioned in Q4 2016 appears completed by Q1 2017. XBIO-101 advanced from general advancement in endometrial and triple-negative breast cancer to specific Phase 2 endometrial recruitment initiation with interim data targeted for end-2018. The ErepoXen Phase 2 data for partnering noted in Q4 was not reiterated in Q1. The PolyXen platform's four licensed molecules (Q4) shifted toward actively seeking PolyXen partnerships and capital in Q1. A new milestone emerged: Shire's SHP656 Phase 1/2 data expected in Q1 2017. Guidance remained vague and uncertainty unchanged at 0.50. The Q4 reference to "transformational Q2 2017 milestones" sets up near-term catalysts. Overall, the company moved from platform establishment toward clinical execution and partnership expansion while continuing to seek capital.

## Latest CallCard · Q1

Xenetic Q1 2017: $4.3M cash, $3M Shire milestone; Shire SHP656 Phase 1/2 data expected this quarter, XBIO-101 Phase 2 endometrial recruitment starting, interim data end-2018; seeking capital and PolyXen partnerships.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights strong foundation, 

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2017 Q1:** Xenetic Q1 2017: $4.3M cash, $3M Shire milestone; Shire SHP656 Phase 1/2 data expected this quarter, XBIO-101 Phase 2 endometrial recruitment starting, interim data end-2018; seeking capital and PolyXen partnerships.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights strong foundation, 
- **2016 Q4:** Xenetic Biosciences reports Q4 2016 progress: $3M Shire milestone, NASDAQ listing, $4M cash, advancing XBIO-101 in endometrial and triple-negative breast cancer, ErepoXen Phase 2 data for partnering, PolyXen platform with four licensed molecules, targeting transformational Q2 2017 milestones.','tone

## Theme arcs

- **Cash position** (improving): Cash increased from $4M to $4.3M
- **Shire partnership** (stable): $3M milestone referenced in both calls; SHP656 Phase 1/2 data expected in Q1 2017
- **XBIO-101 development** (improving): Progressed from advancing in two indications to Phase 2 endometrial recruitment start with interim data timeline
- **PolyXen platform** (stable): Four licensed molecules noted in Q4; actively seeking partnerships and capital in Q1
- **ErepoXen program** (deteriorating): Phase 2 data for partnering mentioned in Q4 but absent in Q1
- **Capital seeking** (stable): Explicitly noted in Q1; implied in Q4 with transformational milestones targeting
- **NASDAQ listing** (resolved): Mentioned as achieved in Q4; not discussed in Q1

## Guidance path

2016 Q4:vague → 2017 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/XBIO`